Q-omics provides the consensus-scored PCDH17 profile across patient tissues and cancer cell-line models. PCDH17 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PCDH17 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, PCDH17 protein abundance shows 23,390 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRP, KIRC, and HNSC as cancer lineages where PCDH17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCDH17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCDH17 survival associations across molecular data types. PCDH17 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCDH17 RNA expression–survival associations across cancer types. High PCDH17 expression shows unfavorable associations in KIRP, UVM, STAD and BLCA, but favorable associations in KIRC and UCS. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PCDH17 RNA expression.
This table summarizes PCDH17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PCDH17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCDH17 shows lower tumor expression in LUSC and LUAD and higher tumor expression in KIRC, HNSC, COAD and LIHC. The KIRC box plot shows higher PCDH17 RNA expression in tumor versus normal tissue (log2 FC = +2.219, t-test p < 0.001).
This table shows molecular features associated with PCDH17 in patient tissues and cancer cell lines. In patient samples, PCDH17 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, PCDH17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
